India’s Latest Patent Brawl Takes Another Twist As Natco Challenges BMS
This article was originally published in PharmAsia News
Natco claims its product does not infringe on Bristol’s patent for Sprycel, and that it did not defy a court order by launching its product in India.
You may also be interested in...
Roche Hits A Wall With Its Tarceva Patent Claims In India; Novartis Moves Supreme Court For Glivec Rights
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.